Copeptin is an independent prognostic factor for transplant‐free survival in cirrhosis. (24th November 2015) - Kerbert, Annarein J. C.
Abstract: Background & Aims: Copeptin is a stable cleavage product of the arginine vasopressin (AVP) precursor and is equimolarly secreted with AVP. Copeptin is currently considered a reliable prognostic marker in a wide variety of diseases other than cirrhosis. We aimed to investigate the association between severity of cirrhosis and copeptin concentrations and to confirm whether copeptin is of prognostic significance in cirrhosis. Methods: One hundred and eighty‐four cirrhotic patients hospitalized in two tertiary referral centres were studied. Serum copeptin was measured in samples obtained at hospital admission. Differences in serum copeptin between Child‐Pugh classes were evaluated using the Kruskal–Wallis test. Cox proportional hazard regression and Kaplan–Meier analyses were performed to evaluate associations of copeptin and other possible prognostic factors with 6‐ and 12‐month mortality. Results: Median serum copeptin (interquartile range) increased significantly through Child‐Pugh classes A [5.4 (3.1–10.7) pmol/L], B [9.6 (6.0–17.3) pmol/L] and C [13.8 (5.8–34.1) pmol/L, P < 0.01]. Patients with serum copeptin >12.3 pmol/L displayed significantly higher mortality rates at 6 and 12 months as compared to those with serum copeptin ≤12.3 pmol/L (Log‐rank test: P < 0.01). Serum copeptin >12.3 pmol/L was significantly associated with mortality, particularly at 6 months, independently of age, clinical parameters and Model for End stage Liver Disease (MELD), MELD‐sodium and Child‐Pugh score. Conclusions: Serum copeptin concentration increases significantly along with the severity of cirrhosis as defined by the Child‐Pugh classification. A high serum copeptin concentration predicts survival, particularly at 6 months, independently of liver‐specific scoring systems in a heterogeneous population of hospitalized cirrhotic patients.